Metallothionein and cadmium in human kidney cortex: influence of smoking

Twenty Element Concentrations in Human Organs Determined by Two-Jet Plasma Atomic Emission Spectrometry

In this paper, we have performed determination of the concentration of twenty elements in seven human organs (spleen, liver, kidney, muscle, heart, lungs, and brain) using two-jet plasma atomic emission spectrometry. The method allows multielemental analysis of solid samples without wet acid digestion. Before analysis, all human organs were first dried, ground to powders, and carbonized. The relative content of elements in each of the seven organs was very different depending on the donor. The average content of twenty elements in various organs varied in the following ranges (μg/g of dry weight): Ag (<0.02–0.2), Al (2.1–263), B (<0.5–2.5), Ca (323–1650), Cd (<0.1–114), Co (<0.2–1.0), Cr (<0.5–4.0), Cu (4.2–47), Fe (156–2900), Mg (603–1305), Mn (0.47–8.5), Mo (<0.2–4.9), Ni (<0.3–3.1), Pb (<0.3–1.9), Si (31.6–2390), Sn (<0.3–3.2), Sr (0.2–1.0), Ti (<2–31, mainly in lungs), and Zn (120–292). The concentration range of Ba in organs of five donors was <0.2–6.9 and 2.0–5600 for one donor with pneumoconiosis (baritosis). The maximum element contents were found, respectively, in the following organs: Al, B, Cr, Ni, Si, Sn, Sr, Ti (lungs), Fe (lungs and spleen), Mn (liver and kidney), Ag and Mo (liver), Ca (lungs and kidney), Cu (brain), Cd (kidney), Pb (brain), and Zn (liver, kidney, and muscle). The minimal content of elements was observed, respectively, in the following organs: Ag (all organs except liver), Ba (spleen, muscles, and brain), Ca and Mg (liver), Si (liver, muscle, and brain), Cd and Sr (heart and brain), Al, Cu, Fe, and Mn (muscle), and Zn (spleen and brain). The analysis of possible biological role and reasons for the increased content of some elements in the organs analyzed was carried out.

Cadmium concentration and metallothionein expression in prostate cancer and benign prostatic hyperplasia of humans

BACKGROUND/PURPOSE

Cadmium (Cd) causes various genitourinary disorders and is a carcinogen for prostate cancer. Metallothionein (MT) is a protein that detoxifies heavy metals. We evaluated changes in Cd concentration and MT expression in human prostate cancer (CaP) and benign prostatic hyperplasia (BPH). Our goal was to clarify the relationship between Cd concentration and MT expression in prostatic diseases.

METHODS

The experimental group consisted of 18 patients who underwent radical prostatectomy for CaP. The control group consisted of 35 patients who underwent transurethral resection of the prostate for BPH. Tissue samples were acquired from the gross tumor site and from resected chips. We determined Cd concentration by atomic absorption, MT expression by immunoblotting, and immunohistochemical staining. The significance of between-group differences for these outcomes was analyzed using Student's t tests.

RESULTS

There was no statistically significant difference in Cd concentration between the CaP and BPH groups. Immunoblots from both groups revealed a single band. The relative intensity of the MT band was 0.58 +/- 0.09 in the BPH group and 0.17 +/- 0.03 in the CaP group. MT expression in patients with BPH was 3.4-fold higher than in those with CaP.

CONCLUSION

MT may bind heavy metals and protect patients from CaP. Additional studies are needed to reveal the factors that influence the expression of MT in prostate epithelial cells, and to analyze the free and compound forms of Cd at the same time.

PF1070A, a novel and potent inducer of the synthesis of metallothionein

Using mouse Ltk(-) cells (L13-17 cells) that had been transfected with a plasmid in which the lacZ gene had been ligated downstream of 1.4 kbp of the sequence of the promoter of the mouse gene for metallothionein-I (MT-I) as a reporter gene, we examined 268 organic compounds for the ability to activate this promoter. We found that PF1070A, an antibiotic produced by Humicola sp., efficiently activated the MT promoter and caused marked enhancement of beta-galactosidase activity in L13-17 cells. The extent of activation by PF1070A was almost equivalent to that by of zinc ions, the most effective known inducer of the synthesis of MT. PF1070A also caused marked elevation of the levels of the mRNA for MT and of MT itself in L13-17 cells. A similar result was obtained in human HeLa-S3 cells. When PF1070A was added to the culture medium simultaneously with cadmium ion or dexamethasone, the level of expression of the reporter gene was markedly elevated, compared to the level of expression induced by each agent independently. The effect of PF1070A was reduced considerably by deletion of nucleotides at positions -150 and -149 from the site of initiation of transcription in the promoter region of the MT gene and also by deletion of the seven bases located at positions -49 to -43. Since no known cis element was found in these two regions, PF1070A might be a new type of inducer of MT synthesis that promotes expression of the gene for MT via a mechanism completely different from those exploited by other known agents. These results also suggest the presence of a system for control of transcription of the gene for MT that has not previously been recognized. Both cadmium ions and bismuth ions induce the synthesis of MT by acting on the metal response element (MRE). Bismuth ions had no significant effect on the promoter activity that had already reached a maximum level in response to treatment with the optimal concentration of cadmium ion. By contrast, PF1070A further and markedly increased the promoter activity. This result suggests that it is possible to increase the concentration of MT in tissue using PF1070A as an inducer even in cases where the MRE-mediated activation of the MT promoter has already been induced by the accumulation of cadmium, as is the case in a clinical setting. PF1070A may prove to be an excellent inducer of MT synthesis that is effective and clinically applicable. Moreover, use of PF1070A in combination with salts of heavy metals might be useful in controlling expression of a transfected gene that is regulated by the MT promoter since PF1070A can activate the MT promoter to an extent that cannot be achieved with heavy metal ions alone, when PF1070A is used in combination with zinc ions at a concentration of the latter considerably below the toxic level.

Metal composition of human hepatic and renal metallothionein

This article is based on data on the levels of metals (Cd, Zn, Cu) and metallothionein (MT) determined radiochemically with 203Hg in renal cortex and liver of 137 autopsy cases. From this number, for 23 cases, the gel filtration of the cytoplasmic fraction of the organs was performed. The molar content of metals in the MT fraction (Sephadex G-50) amounted to 46.9, 50.2, and 2.0% for Cd, Zn, and Cu in renal cortex, respectively, and to 8.3, 83.6, and 9.1% for Cd, Zn, and Cu in the liver, respectively. In parallel with the increase of Cd and MT in renal cortex, increasing saturation was found of the MT fraction by Cd, occurring at the expense of Zn and Cu. Equimolar amounts of Cd and Zn in the MT fraction are found at Cd level of 0.5 micromol Cd/g wet wt of renal cortex. In the liver, analogous dependency (elevation of %Zn, depression of %Cd and %Cu) were observed in relation to Zn and MT levels in this organ. The basic level of Zn (not bound with MT) was estimated at 0.5 micromol/g for both renal cortex and liver. A deficit of non-MT Zn in kidneys is proposed as an alternative mechanism of toxic Cd action.

Metal accumulation in human kidney cortex: mutual interrelations and effect of human factors

1. Different metals were analysed in 77 post mortem samples of human renal cortex. 2. The concentrations of the metallic ions conformed to known distribution frequencies. In abnormal cases calculations were based on non parametric techniques. 3. There was no appreciable difference between the values found for each element and those described by other authors in other populations. 4. Statistically established correlations indicated that Zn was the element which was most strongly related to the others. 5. The influence of individual factors on metal concentrations was considered. Significant differences occurred only in Pb between sexes, and in Cd with age. There was no sign that drug abuse influenced the accumulation of metals in renal cortex.

Cadmium, zinc, copper and metallothionein levels in the kidney and liver of humans from central Poland

Cd, Zn, Cu, and metallothionein (MT) levels have been determined in the renal cortex and liver of 70 persons who died in Lodz and its surroundings in the years 1985-1989. The mean concentrations were: 44.9±28.6 µg Cd/g, 52.0±16.7 µg Zn/g, 2.4±1.0 µg Cu/g, 0.79±0.40 µmol Hg/g, and 3.5±1.8 µg Cd/g, 66.7±30.5 µg Zn/g, 4.9±2.1 µg Cu/g, 0.50±0.38 µmol Hg/g wet tissue in renal cortex and liver, respectively, with mean age 54.0±13.8. Smokers showed 2.4 times higher levels of Cd in the renal cortex than non-smokers. The mean body burden of Cd was 33.4±17.3 mg. Smoking increases it twofold from 22.0 mg in non-smokers to 41.8 mg in smokers.

Cadmium, zinc, copper, and metallothionein levels in the kidney and liver of inhabitants of upper Silesia (Poland)

The levels of Cd, Zn, Cu and metallothionein (MT) were determined in renal cortex and liver of 75 subjects decreased in the period 1986-1989 in the area of Upper Silesia (Katowice). The mean age of the population studied was 53.6 +/- 14.6 years. The determined levels (mean +/- SD) were: 43.1 +/- 23.5 micrograms Cd/g; 52.5 +/- 17.4 micrograms Zn/g; 2.2 +/- 0.7 microgram Cu/g; 0.80 +/- 0.36 mumol Hg/g in renal cortex and 3.5 +/- 2.5 micrograms Cd/g; 82.8 +/- 34.3 micrograms Zn/g; 4.5 +/- 2.6 micrograms Cu/g; 0.69 +/- 0.44 mumol Hg/g in the liver. The level of Cd in renal cortex was 40% higher in smokers compared to nonsmokers and was independent of the gender. Whole-body retention of Cd was 34.1 +/- 18.5 mg; smoking elevated the value from 27.1 to 38.2 mg. Compared with a similar study made in central Poland (Lódź), a significant difference was found only regarding the level of Zn and MT in the liver, pointing to the possibility that exposure to this element in the region of Upper Silesia may be higher.

Cadmium nephrotoxicity in human proximal tubule cell cultures

Human proximal tubule kidney cells grown in a serum-free tissue culture medium were exposed to concentrations of CdCl2 in a range of 0.5 to 10 micrograms/ml. Cells were observed from 1 to 20 d upon initiation of cadmium in the culture fluid. Both confluent and subconfluent populations of cells were treated and evaluated for cytotoxicity. Both populations exhibited a concentration-dependent toxicity to ionic cadmium. For cells treated with 2.0 to 10 micrograms/ml Cd, the decreases in cell numbers were largely irreversible. However, cells treated with Cd in a range of 0.5 to 1.0 micrograms/ml exhibited a partial recovery of cell number and control morphology. In this range, recovery was more efficient in the subconfluent cultures. Fine structural alterations in Cd-treated tubule cells included condensation of nuclear chromatin, loss of microvilli structure, disorganization of lateral membrane interdigitation, as well as decreased uptake of aminoglycoside antibiotics as evidenced by decreased numbers of myeloid bodies in these cells. The results of this study imply that use of a human proximal tubule culture system has potential in discerning structural and functional effects of cadmium as well as other nephrotoxic metals and compounds on the human kidney.

Cadmium and metallothionein levels in the liver of humans exposed to environmental cadmium in Upper Silesia, Poland

The area of Upper Silesia is the most industrialized region in Poland. The concentrations of cadmium (Cd), zinc (Zn), copper (Cu) and metallothionein (MT) in autopsy samples (n = 29) of liver from the inhabitants of that area were determined. The metal levels varied in the ranges of 0.5-11.9 micrograms Cd/g, 45.3-221.6 micrograms Zn/g, 1.4-10.3 micrograms Cu/g. The concentration of MT determined by the Hg-method was high: 0.38-2.86 mumol Hg/g. A positive linear relationship was observed between Zn and MT levels.

Metallothionein, cadmium, copper and zinc levels of human and rat tissues

Metallothionein (MT), zinc (Zn), copper (Cu) and cadmium (Cd) were determined in 10 tissues (brain, heart, kidney cortex, liver, lung, muscle, pancreas, small intestine, spleen and stomach) from human autopsies (10 male individuals, mean age 43 +/- 9 years, all smokers) and Wistar rats. The mean tissue concentrations of MT in the human samples varied between 3.8 and 495 micrograms/g wet weight in spleen and kidney cortex, respectively. In most tissues human MT levels were high as compared to rats; particularly in liver and kidney cortex human MT levels exceeded those of rats about 25- and 10-fold, respectively. Positive linear relationships were observed between Zn or Cu and MT in human liver and between Cd and MT in human kidney cortex.

D-penicillamine induces rat hepatic metallothionein

Intraperitoneal injection of D-Penicillamine (D-PA) at a dose range of 20-500 mg/kg increased rat hepatic but not renal and pancreatic metallothionein (MT). Elevated MT predominantly contained Zn. Maximal induction was obtained 18 h after a single injection of 200 mg D-PA/kg resulting in 148 +/- 18 micrograms MT/g liver which was 16.4-times the control level of 9 +/- 2 micrograms MT/g. At 48 h after injection, MT declined to 18 +/- 9 micrograms MT/g liver. At maximal MT increase the content of total hepatic Zn but not of Cu was elevated. Increased amounts of Zn in liver homogenate, cytosol and MT could be detected approximately 4 h after injection of 200 mg D-PA/kg. Concomitantly there was a decrease in Zn bound to cytosolic non-MT ligands. All Zn changes reversed at 18 h. These data show that already single doses of D-PA cause induction of Zn-thionein in rat liver and lead to synchronous redistribution of Zn from endogenous sources to newly synthesized MT.